RARECast: Novel Approach to Treat Rare Disease May Lead to Drugs for Common Ones
June 24, 2016
Mitochondria, the powerhouses of the cell, play a critical role in a range of rare and common diseases. Retrotope, a development-stage company, thinks it’s found a way to repair the damage done by various disease processes to mitochondria. The company is just concluding an early-stage trial of its experimental therapy to treat the rare disease Freidreich’s ataxia. We spoke to Bob Molinari, CEO of Retrotope, and Harry Saal, Chairman of the company, about mitochondrial diseases, the approach the company is taking, and why its work may have broad implications for a wide range of degenerative diseases.
Daniel S. Levine is an award-winning business journalist who has reported on the life sciences, economic development, and business policy issues throughout his 25-year career. He founded Levine Media Group in 2013 to provide strategic communications to life sciences companies. He is host of The Bio Report and RARECast podcasts, a senior fellow at the Center for Medicine in the Public Interest, and a member of the advisory board of the California Biotechnology Council.
Sign up for updates straight to your inbox.